Cancer Stem Cell News Volume 4.29 | Aug 5 2015

Ceacam1L Modulates STAT3 Signaling to Control the Proliferation of Glioblastoma-Initiating Cells
Researchers demonstrated that carcinoembryonic antigen-related cell adhesion molecule Ceacam1L acts as a crucial factor in glioblastoma-initiating cells maintenance and tumorigenesis by activating c-Src/STAT3 signaling. [Cancer Res] Abstract

Cytomegalovirus Immediate-Early Proteins Promote Stemness Properties in Glioblastoma
Investigators showed how human cytomegalovirus immediate-early proteins are preferentially expressed in glioma stem-like cells where they colocalize with the other glioblastoma stemness markers, CD133, Nestin, and Sox2. [Cancer Res] Abstract

Fluorescent CSC Models Evidence that Targeted Nanomedicines Improve Treatment Sensitivity of Breast and Colon Cancer Stem Cells
Researchers developed a novel in vitro fluorescent cancer stem cell (CSC) model that allowed them to visualize these cells in heterogeneous population and to monitor CSC biological performance after therapy. [Nanomedicine] Abstract | Graphical Abstract

USP44⁺ Cancer Stem Cells Subclones Contributed to Breast Cancer Aggressiveness by Promoting Vasculogenic Mimicry
Breast cancer stem cells (CSCs) presented the centrosome amplification phenotype and ubiquitin-specific protease 44 (USP44) upregulation. USP44 expression contributed to the establishment of bipolar spindles in breast CSCs with supernumerary centrosomes by localizing at pole-associated centrosomes. [Mol Cancer Ther] Abstract

Heat Shock Factor 1 Induces Cancer Stem Cell Phenotype in Breast Cancer Cell Lines
Researchers explored whether high heat shock factor 1 (HSF1) expression might be associated with the cancer stem cell (CSC) phenotype. They also evaluated the effects of HSF1 over-expression and knock-down on sphere formation and CSC marker expression in breast cancer cell lines. [Breast Cancer Res Treat] Full Article

4-Acetylantroquinonol B Inhibits Colorectal Cancer Tumorigenesis and Suppresses Cancer Stem-Like Phenotype.
Researchers hypothesized that 4-acetylantroquinonol B (4-AAQB) may play an active role in the suppression of cellular transformation, tumor aggression and progression, as well as chemoresistance in colorectal carcinoma. They investigated the antiproliferative role of 4-AAQB and its underlying molecular mechanism. [Toxicol Appl Pharmacol] Abstract

Microenvironmental Modulation of Decorin and Lumican in Temozolomide-Resistant Glioblastoma and Neuroblastoma Cancer Stem-Like Cells
Scientists determined whether the small leucine-rich proteoglycans decorin and lumican are recruited in cell plasticity and microenvironmental adaptation of differentiated cancer cells induced towards stem-like phenotype. [PLoS One] Full Article

JNK Is Required for Maintaining the Tumor-Initiating Cell-Like Properties of Acquired Chemoresistant Human Cancer Cells
Investigators determined the impact of c-Jun N-terminal kinase (JNK) on the tumor-initiating cell-like properties of acquired chemoresistant human cancer cells. [Acta Pharmacol Sin] Abstract

Upregulation of miR-130b Enhances Stem Cell-Like Phenotype in Glioblastoma by Inactivating the Hippo Signaling Pathway
Investigators report that miR-130b directly repressed MST1 and SAV1 expression in human glioblastoma cells. Overexpression of miR-130b induced hyperactivation of the YAP/TAZ and enhanced expression of the Hippo signaling downstream genes CTGF and the pluripotency associated markers, including CD133, SOX2, Nanog, MYC and BMI1, leading to promotion of glioblastoma stem cell phenotype. [Biochem Biophys Res Commun] Abstract

Novel Small Molecule Inhibitors of Cancer Stem Cell Signaling Pathways
The development of novel chemotherapeutic agents and proteins specifically targeting cancer stem cells are attractive pharmaceutical candidates. The authors describe small molecule inhibitors of stem cell pathways Wnt, Notch and Hedgehog, and their recent chemotherapy clinical trials. [Stem Cell Rev] Abstract

Visit our reviews page to see a complete list of reviews in the cancer stem cell research field.

Eisai’s In-House Developed Novel Anticancer Agent Lenvima^® Receives Breakthrough Therapy Designation from U.S. FDA for Renal Cell Carcinoma
Eisai Co., Ltd. announced its U.S. subsidiary Eisai Inc. has received a breakthrough therapy designation from the U.S. Food and Drug Administration (FDA) for its in-house developed novel anticancer agent Lenvima^® (lenvatinib mesylate, “lenvatinib”) for the potential indication of advanced and/or metastatic renal cell carcinoma. [Eisai Co., Ltd.] Press Release

From our sponsor: Learn about detecting cancer stem cells with ALDEFLUOR™. Watch the webinar.

Food and Drug Administration (United States)

Center for Biologics Evaluation and Research (United States)

European Medicines Agency (European Union)

Medicines and Healthcare Products Regulatory Agency (United Kingdom)

Therapeutic Goods Administration (Australia)

Visit our events page to see a complete list of events in the cancer stem cell community.

NEW Postdoctoral Position – Experimental Oncology/Stem Cell Biology (Academia Medical Center)

Research Associate – Cell Separation (STEMCELL Technologies Inc.)

Postdoctoral Research Fellow – Cancer Research (Fred Hutchinson Cancer Research Center)

Postdoctoral Fellowship – Brain Tumor Biology and Stem Cells (Universität Basel)

Postdoctoral Fellow – Cancer Research (National University of Singapore)

Postdoctoral Cancer Research – Molecular Targets for Tumor Therapy (University of Würzburg)

Higher Scientific Officer – Cancer Proteomics (Institute of Cancer Research)

Postdoctoral Positions- Cancer Research (Rutgers University)

Postdoctoral Research Associate – Breast Stem Cell Biology (University of Miami Miller School of Medicine)

Postdoctoral Fellowships – Cancer Research (German Cancer Research Center)

Professor – Cancer Stem Cells (Dalian Medical University)

Recruit Top Talent: Reach more than 60,000 potential candidates by posting your organization’s career opportunities on the Connexon Creative Job Board at no cost.